TE Tirzepatide Editorial

Ranking

Best Tirzepatide Providers

Direct answer

This ranking orders tirzepatide providers by a computed effective monthly cost, and only includes records where mandatory-fee inclusion is confirmed so the comparison is like-for-like. Providers whose advertised price cannot be normalised are excluded and listed with reasons. No editorial score is applied, and no provider has any commercial relationship with this publication.

Key takeaways

  • Ranking uses computed cost only — there is no subjective editorial score to hide preference in.
  • Only providers with confirmed fee inclusion are ranked; the rest are excluded with published reasons.
  • Advertised 'from' prices that exclude fees appear in a separate, clearly-labelled table.
  • Cost alone does not identify the best provider — pharmacy and clinician verification remain incomplete.
  • No provider pays for inclusion, position, or wording.
Current regulatory status — compounded tirzepatide. The FDA determined the tirzepatide shortage resolved on 2 October 2024 and reaffirmed it by declaratory order on 19 December 2024. Enforcement discretion for compounding ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities, and a federal court upheld the determination in May 2025. Federal law prohibits compounding a copy of a commercially available approved drug outside a shortage, so routine compounded tirzepatide is no longer permitted. Full timeline and sources.
Ranking snapshot
CriterionOverall, by verified cost transparency
Records reviewed24
Eligible5
Excluded19
OrderingComputed cost only — no editorial score
Methodologyv1.0
Publisher relationship with providersNone
Partially verified
Reviewed by Kim Callender, NP, FNP-BC
Published 2026-07-22
Editorially updated 2026-07-22
Fact verified 2026-07-22
Price verified 2026-07-20
Dataset snapshot 2026-07-22
Methodology v1.0

Which providers rank highest?

Ranked providers — like-for-like effective monthly cost
#ProviderEffective $/moBasisMandatory feesPrice verified
1TRYM Health$125complete published commitment ladder for the standard injection: medication included, no separate membership or shipping feeNo hidden membership/shipping fees advertised2026-07-20
2NexLife$186complete published commitment ladder for the standard injection: medication included, no separate membership or shipping feeNo separate membership fee; consultations and expedited shipping adver2026-07-20
3Fridays$240advertised monthly rate with medication included and no separate membership feeGenerally advertised as all-inclusive2026-07-20
4Mochi Health$278effective recurring cost: medication plus every mandatory fee, computed from the captured componentsMembership $39 first month, then $79/month; shipping advertised includ2026-07-20
5Eden$298effective recurring cost: medication plus every mandatory fee, computed from the captured componentsMembership separate2026-07-20
TRYM Health125/moNexLife186/moFridays240/moMochi Health278/moEden298/mo
Effective monthly tirzepatide cost for the 5 records that met the eligibility test. Lower is cheaper; bases are shown in the table.

Why does this ranking refuse to name an overall winner?

Because "best" would require weighting cost against pharmacy verification, clinician access, dose coverage, and cancellation terms — and four of those five are unverified across the entire dataset. Any overall score would therefore be mostly cost with a decorative wrapper, presented as though it measured something broader.

Ordering by computed cost and saying so is less impressive and more accurate. When the pharmacy and policy fields are verified, categories that depend on them will be ranked on their own terms rather than folded into a composite.

What separates a like-for-like price from an advertised one?

A like-for-like figure is the amount that leaves your account every month once every mandatory charge is included. An advertised figure is whatever the provider chose to put on the pricing page, which frequently covers medication only. Two providers can advertise $99 and $186 and cost $178 and $186 respectively.

This ranking only orders records where that distinction has been resolved from public information. The rest appear in the exclusion table with the reason.

What was the sample, and what was excluded?

Sample: 24 provider records reviewed, 5 eligible for this category, 19 excluded. Methodology v1.0; each record carries its own price-verification date.

Excluded records and the reason each was excluded
ProviderReason for exclusion
OrderlyMedsAdvertised as a “from” starting price, not a recurring all-in cost
Henry MedsPrice stated in free text that cannot be normalised
Ivím HealthPrice stated in free text that cannot be normalised
AmblePrice stated in free text that cannot be normalised
Lavender Sky HealthAdvertised as a “from” starting price, not a recurring all-in cost
Fifty 410Advertised as a “from” starting price, not a recurring all-in cost
ShedRx / SHEDAdvertised as a “from” starting price, not a recurring all-in cost
Remedy MedsMandatory-fee inclusion not confirmed in the captured source
WillowAdvertised as a “from” starting price, not a recurring all-in cost
GobyMedsPrice stated in free text that cannot be normalised
Zappy HealthPrice stated in free text that cannot be normalised
SlimDownRxPrice stated in free text that cannot be normalised
Valhalla VitalityPrice stated in free text that cannot be normalised
Hims & HersAdvertised figure covers medication only; mandatory care or membership fees billed separately
Ro BodyPrice stated in free text that cannot be normalised
WeightWatchers ClinicAdvertised figure covers medication only; mandatory care or membership fees billed separately
Noom MedPrice stated in free text that cannot be normalised
LifeMDAdvertised as a “from” starting price, not a recurring all-in cost
FoundAdvertised as a “from” starting price, not a recurring all-in cost

Ranking methodology

Every ranking on this site uses one shared eligibility function, applied identically to all providers. A record qualifies only when a recurring tirzepatide cost can be computed from public information on a like-for-like basis — meaning mandatory fees are either included or confirmed absent.

Records are excluded when pricing is approximate, stale, introductory-only, fee-unknown, dose-unknown, conflicting, or stated in free text that cannot be normalised. Every exclusion is published with its reason below, so the sample is auditable rather than asserted.

Rankings are ordered by computed cost alone. There is no editorial score, no weighting, and no manual adjustment, because a subjective score is exactly where undisclosed preference would hide.

Relationship disclosure. No provider on this site has any financial, ownership, affiliate, referral, or sponsorship relationship with Tirzepatide Editorial. No provider can pay for inclusion, position, or a favourable description.

What does the market actually charge?

TRYM Health125NexLife186Fridays240Mochi Health278Eden298$/month
Only providers whose captured source states a recurring price including medication and every mandatory fee appear here. 19 of 24 records are excluded, each with a published reason.
Data for: Verified all-in monthly cost, standard injection
Group$/month
TRYM Health125
NexLife186
Fridays240
Mochi Health278
Eden298
Advertised medication price$99Monthly membership fee+$79Consultation fee$0Shipping$0Effective monthly cost$178
A worked example of the most common pricing pattern in this market: a low advertised medication price with a separate recurring membership. The advertised figure and the real figure differ by 80% here, which is why this site ranks on computed cost rather than headline price.
Data for: How a $99 advertised price becomes a real monthly cost
ComponentAmountRunning total
Advertised medication price$99$99
Monthly membership fee$79$178
Consultation fee$0$178
Shipping$0$178
0$1440$2880$4320$5760$TRYM HealthNexLifeFridaysStart6 mo12 mo18 mo24 mo
Cumulative spend over the horizon that the withdrawal evidence implies. Differences that look small monthly compound substantially across two years.
Data for: Two-year cumulative cost at verified rates
SeriesStart6 mo12 mo18 mo24 mo
TRYM Health0$750.0$1500.0$2250.0$3000.0$
NexLife0$1116.0$2232.0$3348.0$4464.0$
Fridays0$1440.0$2880.0$4320.0$5760.0$
How to read the prices on this page. The pricing captured below reflects what providers advertised at the verification date shown. Because routine compounding of tirzepatide is no longer permitted following resolution of the shortage, an advertised compounded price should be treated as a question rather than an offer: ask what product is actually being dispensed, under what legal basis, and by which licensed pharmacy. Some sellers market "personalised" preparations — typically by adding an ingredient such as vitamin B12 or varying the dose — and the FDA treats products close to the approved dose as essentially copies regardless of such changes.
What the approved-product route costs. With routine compounding of tirzepatide no longer permitted, the live options are insurance coverage, manufacturer savings programmes, and the manufacturer's direct cash channel, which starts at $299 per month for the starting dose against a retail list price near $1,086. Full pathway comparison and per-dose pricing · coverage and appeals.

What makes a provider genuinely good rather than merely cheap?

Cost is the dimension this site can currently measure, which is not the same as the dimension that matters most. A provider that charges $186 with an unnamed pharmacy and no stated cancellation terms may be a worse choice than one charging more with both disclosed. The ranking is honest about ordering on the one axis that is verifiable rather than inventing a composite score across axes that are not.

The dimensions that would complete this picture are pharmacy identity and licensure, the clinical model and who reviews intake, dose coverage across the full labelled range, and the contractual terms governing cancellation and refunds. All four are unverified across this dataset. Until they are, a reader should treat the cost ranking as one input among several rather than as a recommendation.

How sensitive is this ranking to its own assumptions?

A ranking that changes order when a single assumption moves is fragile, and a reader deserves to know which assumptions are load-bearing. The table below re-runs the ordering under three alternative assumptions to show which conclusions survive and which do not. This is the analysis most commercial comparison sites omit, because a ranking that visibly depends on its own choices is harder to present as authoritative.

The same providers under committed and month-to-month assumptions
ProviderCommitted monthlyMonth-to-monthCommitted yearFlexible year
TRYM Health$125$180$1,500$2,160
NexLife$186$215$2,232$2,580
Fridays$240$240$2,880$2,880
Mochi Health$278$278$3,336$3,336
Eden$298$298$3,576$3,576

The ordering is stable across both assumptions in the current dataset: TRYM Health is lowest whether the comparison uses committed pricing or month-to-month pricing. That stability matters because it means the leading position does not depend on a reader accepting a long prepayment. Where a ranking only holds under a twelve-month commitment, the commitment is doing the work rather than the price, and this site would say so.

What happens to this ranking when the excluded records are resolved?

19 of 24 records are currently outside the ranked set. That is a large proportion, and it would be misleading to present the ranked table as a picture of the whole market without saying what the excluded records might do to it. Each exclusion category resolves differently.

What resolving each exclusion category would do to this ranking
Exclusion categoryCountProvidersHow it would resolve
From Teaser7OrderlyMeds, Lavender Sky Health, Fifty 410, ShedRx / SHED, Willow, LifeMD, FoundThese providers advertise a starting price. Resolution requires confirming what the same programme costs at a standard maintenance dose on a recurring basis. Historically, resolved 'from' prices land materially above the
Not Normalisable9Henry Meds, Ivím Health, Amble, GobyMeds, Zappy Health, SlimDownRx, Valhalla Vitality, Ro Body, Noom MedThese providers publish pricing in a form that cannot be reduced to a recurring monthly figure at all. Resolution requires a direct written quotation.
Fee Unknown1Remedy MedsThese providers state a monthly figure without confirming whether mandatory fees are included. Resolution could move them in either direction, which is precisely why they are not ranked on an assumption.
Medication Only2Hims & Hers, WeightWatchers ClinicThese providers quote medication separately from a care or membership charge. Resolution requires the sum. Because the separate charge is recurring, the resolved figure is necessarily higher than the advertised one.

The honest summary is that the ranked set is a floor rather than a complete market picture. It shows the providers whose costs can currently be compared, ordered correctly. It does not show that no cheaper option exists anywhere — it shows that no cheaper option has published enough information to be verified. Those are different claims, and conflating them is the most common failure in this category.

What should you verify before acting on any ranking?

A ranking is a starting point built from public information at a moment in time. These checks convert it into a decision you can rely on.

  • Confirm the recurring price on the provider's own checkout, not on its marketing page.
  • Ask what the price becomes after any introductory period ends.
  • Get a complete list of mandatory fees in writing.
  • Ask what the price becomes at 10 mg and 15 mg.
  • Ask which pharmacy compounds the medication and confirm its licence with the state board.
  • Read the cancellation terms before prepaying for any multi-month plan.
  • Check the price-verification date on this page against today's date.

If a provider's answers differ from what is published here, that is a correction this site wants. Submit it with the documentation and the record will be updated with a dated note.

What does this page cover, and what does it deliberately leave out?

This page addresses Separate categories, scoring, sample and eligible and excluded providers, organised around the primary question of best tirzepatide providers. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.

Scope of this page and the basis for each element
ElementTreatment hereEvidence basis
Separate categoriesCovered on this pageCaptured record
ScoringCovered on this pageCaptured record
SampleCovered on this pageCaptured record
Eligible and excluded providersCovered on this pageCaptured record
Individualized clinical instructionDeliberately not coveredBelongs with each provider's own checkout

What are the limits of what this page can tell you?

Every page on this site rests on a specific ranking methodology and its inputs, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.

Specific limitations.
  • The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for each provider's own checkout.
  • Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
  • Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
  • Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.

What would change the conclusion on this page?

The following would trigger a revision to this page, recorded in its change history:

  • New primary evidence bearing directly on best tirzepatide providers.
  • A change to FDA labelling affecting any statement made above.
  • A verified correction submitted through the corrections process and accepted on the evidence.
  • A material change to a captured record, including a price, term, or regulatory status.
  • Completion of a verification currently marked pending, which would replace a gap with a stated fact.

What do the technical terms on this page mean?

Definitions for the 6 technical terms this page uses, including 503A, 503B, DOI, compounded — in the specific sense used above.

Terms used on this page
503AA pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility.
503BAn outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval.
DOIDigital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website.
compoundedPrepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial.
effective monthly costThe recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking.
membership feeA recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper.

Frequently asked questions

How do you decide the best tirzepatide provider?

By computed recurring cost among records where mandatory-fee inclusion is confirmed. No editorial score is applied, because four of the five fields that would justify one are unverified.

Why is there no overall score out of ten?

Because a composite score built mostly from cost, presented as measuring more than cost, would mislead. Ordering by the figure actually computed is more honest.

Can a provider pay to appear here?

No. There is no financial, affiliate, referral, or sponsorship relationship with any provider.

Why are well-known telehealth brands missing?

Because their published pricing cannot be normalised into a comparable recurring figure. Each exclusion is listed with its reason.

Does the top-ranked provider have the best care?

Unknown. Clinician model, pharmacy identity, and dose coverage are unverified across the dataset.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?